Caldwell Trust Co Makes New $1.70 Million Investment in Bristol Myers Squibb Company $BMY

Caldwell Trust Co acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 36,629 shares of the biopharmaceutical company’s stock, valued at approximately $1,696,000.

Several other large investors also recently modified their holdings of the business. New England Asset Management Inc. grew its holdings in Bristol Myers Squibb by 0.8% in the first quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company’s stock worth $2,408,000 after purchasing an additional 305 shares during the period. Commonwealth Retirement Investments LLC boosted its position in shares of Bristol Myers Squibb by 24.6% in the 2nd quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock worth $2,740,000 after purchasing an additional 11,690 shares in the last quarter. Norges Bank purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $1,554,154,000. Sound View Wealth Advisors Group LLC increased its position in Bristol Myers Squibb by 438.0% during the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 307,849 shares of the biopharmaceutical company’s stock valued at $14,250,000 after buying an additional 250,624 shares in the last quarter. Finally, Wealth Quarterback LLC increased its position in Bristol Myers Squibb by 42.6% during the 2nd quarter. Wealth Quarterback LLC now owns 25,443 shares of the biopharmaceutical company’s stock valued at $1,178,000 after buying an additional 7,603 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Trading Up 2.3%

Shares of BMY stock opened at $52.38 on Monday. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The stock has a market capitalization of $106.63 billion, a P/E ratio of 17.69, a P/E/G ratio of 8.02 and a beta of 0.29. The firm’s 50 day moving average is $46.80 and its 200 day moving average is $46.93.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. The firm had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be given a $0.63 dividend. The ex-dividend date is Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a yield of 4.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 83.78%.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of recent research reports. Morgan Stanley reissued an “underweight” rating and issued a $37.00 target price (up from $36.00) on shares of Bristol Myers Squibb in a research note on Friday. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 3rd. Scotiabank reiterated a “sector perform” rating and issued a $53.00 target price (up previously from $45.00) on shares of Bristol Myers Squibb in a research note on Thursday, December 4th. Finally, Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Four investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and an average target price of $54.08.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.